Literature DB >> 5909494

The Vallance-Owen ("synalbumin") insulin antagonist. Reproducibility and reliability of results in nondiabetic and diabetic humans.

L Sherman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5909494     DOI: 10.2337/diab.15.3.149

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


× No keyword cloud information.
  7 in total

1.  The nature of human serum insulin-like activity (ILA)P Characterization of ILA in serum and serum fractions obtained by acid-ethanol extraction and adsorption chromatography.

Authors:  P L Poffenbarger; J W Ensinck; D K Hepp; R H Williams
Journal:  J Clin Invest       Date:  1968-02       Impact factor: 14.808

2.  Synalbumin insulin antagonism and protein synthesis.

Authors:  J S Bajaj; D D Bansal; H O Jindal
Journal:  Acta Diabetol Lat       Date:  1974 Nov-Dec

3.  The nature of the artifactual synalbumin insulin antagonist.

Authors:  G N Holcomb; W E Dulin
Journal:  Diabetologia       Date:  1973-12       Impact factor: 10.122

4.  In vivo effects of the synalbumin insulin antagonist.

Authors:  L Kammerer; J Vallance-Owen
Journal:  Diabetologia       Date:  1968-12       Impact factor: 10.122

5.  [Synalbumin insulin antagonism in northern India].

Authors:  J S Bajaj; D D Bansal; S K Gupta
Journal:  Acta Diabetol Lat       Date:  1971 Mar-Apr

6.  Further studies on the incidence of the synalbumin insulin antagonist.

Authors:  J S Bajaj; D McMaster; J Vallance-Owen
Journal:  Diabetologia       Date:  1971-06       Impact factor: 10.122

7.  Inhibition of glutathione reductase in diabetics and non-diabetics.

Authors:  J Jervell; J Vallance-Owen
Journal:  Diabetologia       Date:  1967-06       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.